Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A method of inhibiting JAK1 and/or JAK2 in a patient suffering from an autoimmune skin disease, comprising administering to the patient a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the compound or salt is administered as a pharmaceutical composition comprising the compound or the salt and a pharmaceutically acceptable carrier.
4. The method of claim 3 , wherein the pharmaceutical composition is suitable for topical administration.
5. The method of claim 3 , wherein the pharmaceutical composition is suitable for oral administration.
6. The method of claim 3 , wherein about 5 to about 1000 mg of the compound, or pharmaceutically acceptable salt thereof, is administered to the patient.
7. The method of claim 2 , further comprising administering to the patient at least one additional therapeutic agent.
8. The method of claim 7 , wherein the therapeutic agent is administered to a patient simultaneously or sequentially.
9. The method of claim 7 , wherein said therapeutic agent is an immunosuppressant.
10. The method of claim 7 , wherein said therapeutic agent is a steroid.
11. The method of claim 7 , wherein said therapeutic agent is a corticosteroid.
12. The method of claim 11 , wherein said corticosteroid is dexamethasone or prednisone.
13. The method of claim 11 , wherein said corticosteroid is dexamethasone.
14. The method of claim 11 , wherein said corticosteroid is prednisone.